Top

Supportive Care in Cancer

Published in:

01-05-2011 | Original Article

The short-term effects of low-level laser therapy in the management of breast-cancer-related lymphedema

Authors: Abuzer Dirican, Oya Andacoglu, Ronald Johnson, Kandace McGuire, Lisa Mager, Atilla Soran

Published in: Supportive Care in Cancer | Issue 5/2011

Abstract

Background

Breast-cancer-related lymphedema (BCRL) is a chronic disease, and currently there is no definitive treatment for it. There are some therapeutic interventions targeted to decrease the limb swelling and the associated problems. Low-level laser therapy (LLLT) has been used in the treatment of post-mastectomy lymphedema since 2007 in the US. The aim of this study is to review our short-term experience with LLLT in the treatment of BCRL.

Method

Seventeen BCRL patients referred to our lymphedema program between 2007 and 2009 were enrolled in this study. All patients had experienced at least one conventional treatment modality such as complex physical therapy, manual lymphatic drainage, and/or pneumatic pump therapy. LLLT was added to patients' ongoing therapeutic regimen. All patients completed the full course of LLLT consisting of two cycles. The difference between sums of the circumferences of both affected and unaffected arms (ΔC), pain score, scar mobility, and range of motion were measured before and after first and second cycles of LLLT sequentially.

Results

All patients were female with a median age of 51.8 (44–64) years. ΔC decreased 54% (15–85%) and 73% (33–100%), after the first and second cycles of LLLT, respectively. Fourteen out of seventeen experienced decreased pain with motion by an average of 40% (0–85%) and 62.7% (0–100%) after the first and second cycle of LLLT, respectively. Three patients had no improvement in pain after LLLT. Scar mobility increased in 13 (76.4%) and shoulder range of motion improved in 14 (82.3%) patients after LLLT. One patient developed cellulitis during LLLT.

Conclusion

Patients with BCRL received additional benefits from LLLT when used in conjunction with standard lymphedema treatment. These benefits include reduction in limb circumference, pain, increase in range of motion and scar mobility. Additionally, two cycles of LLLT were found to be superior to one in this study.

Petrek JA, Heelan MC (2002) Incidence of breast carcinoma related lymphedema. Cancer 83:2776–2781CrossRef

Schrenk P, Rieger R, Shamiyeh A, Wayand W (2000) Morbidity following sentinal lymph node versus axillary lymph node dissection for patients with patients with breast carcinoma. Cancer 88:608–614PubMedCrossRef

Deutsch M, Flickinger JC (2003) Arm edema after lumpectomy and breast irradiation. Am J Clin Oncol 26:229–231PubMedCrossRef

Harris SR, Hugi MR, Olivotto IA, Levine M, Steering Committee for Clinical Practice Guidelines for the Care and Treatment of Breast Cancer (2001) Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. CMAJ 164:191–199PubMed

Donegan W, Spratt J (2002) Surgical techniques. In: Cancer of the breast, 5th edn Saunders, Philadelphia, pp 601–638

Soran A, D'Angelo G, Begovic M, Ardic F, Harlak A, Samuel Wieand H, Vogel VG, Johnson RR (2006) Breast cancer related lymphedema—what are the significant predictors and how they affect the severity of lymphedema? Breast J 6:536–543CrossRef

Moseley AL, Carati CJ, Piller NB (2007) A systematic review of common conservative therapies for arm lymphedema secondary to breast cancer treatment. Ann Oncol 18:639–646PubMedCrossRef

Carati CJ, Anderson SN, Gannon BJ, Piller NB (2003) Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial. Cancer 98:1114–1122PubMedCrossRef

Piller NB, Thelander A (1998) Treatment of chronic postmastectomy lymphedema with low level laser therapy: a 2.5 year follow-up. Lymphology 31:74–86PubMed

10.

Kaviani A, Fateh M, Nooraie RY, Alinagizadeh MR, Ataie-Fashtami L (2006) Low-level laser therapy in management of postmastectomy lymphedema. Lasers Med Sci 21:90–94PubMedCrossRef

11.

Kozanoglu E, Basaran S, Paydas S, Sarpel T (2009) Efficacy of pneumatic compression and low-level laser therapy in the treatment of postmastectomy lymphedema: a randomized controlled trial. Clin Rehabil 23:117–124PubMedCrossRef

12.

Lau RW, Cheing GL (2009) Managing postmastectomy lymphedema with low-level laser therapy. Photomed Laser Surg 27:763–769PubMedCrossRef

13.

Williamson A, Hoggart B (2005) Pain: a review of the three commonly used pain rating scales. J Clin Nurs 14:798–804PubMedCrossRef

14.

Hayes K, Walton JR, Szomor ZR, Murrell GA (2001) Reliability of five methods for assessing shoulder range of motion. Aust J Physiother 47:289–294PubMed

15.

Vercelli S, Ferriero G, Sartorio F, Stissi V, Franchignoni F (2009) How to assess postsurgical scars: a review of outcome measures. Disabil Rehabil 31:2055–2063PubMedCrossRef

16.

Ekim A, Armagan O, Tascioglu F, Oner C, Colak M (2007) Effect of low level laser therapy in rheumatoid arthritis patients with carpal tunnel syndrome. Swiss Med Wkly 137:347–352PubMed

17.

Gur A, Karakoc M, Cevik R, Nas K, Sarac AJ, Karakoc M (2003) Efficacy of low power laser therapy and exercise on pain and functions in chronic low back pain. Lasers Surg Med 32:233–238PubMedCrossRef

18.

Nouri K, Jimenez GP, Harrison-Balestra C, Elgart GW (2003) 585-nm pulsed dye laser in the treatment of surgical scars starting on the suture removal day. Dermatol Surg 29:65–73PubMedCrossRef

19.

Ortu P, LaMuraglia GM, Roberts WG, Flotte TJ, Hasan T (1992) Photodynamic therapy of arteries. A novel approach for treatment of experimental intimal hyperplasia. Circulation 85:1189–1196PubMed

20.

Honmura A, Ishii A, Yanase M, Obata J, Haruki E (1993) Analgesic effect of Ga-Al-As diode laser irradiation on hyperalgesia in carrageenin-induced inflammation. Lasers Surg Med 13:463–469PubMedCrossRef

21.

Piller NB, Thelander A (1996) Low level laser therapy: a cost effective treatment to reduce post mastectomy lymphedema. Lymphology 29:297–300

Title: The short-term effects of low-level laser therapy in the management of breast-cancer-related lymphedema
Authors: Abuzer Dirican
Oya Andacoglu
Ronald Johnson
Kandace McGuire
Lisa Mager
Atilla Soran
Publication date: 01-05-2011
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 5/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-010-0888-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2011

Vitamin E for preventing chemotherapy-induced peripheral neuropathy

Physical activity, quality of life, and the interest in physical exercise programs in patients undergoing palliative chemotherapy

Breast cancer treatment-related lymphedema self-care: Education, practices, symptoms, and quality of life

Effect of massage therapy on stress levels and quality of life in brain tumor patients—observations from a pilot study

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study

Development and pilot testing of a communication aid to assist clinicians to communicate with women diagnosed with ductal carcinoma in situ (DCIS)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer